Miguel Leon-Sanz

Dr. Miguel Leon-Sanz

Clinical Nutrition Unit, Department of Endocrinology and Nutrition, Hospital Universitario 12 de Octubre, Avenida de Córdoba, 28041 Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Clinical Nutrition
Verified
Journal Article
Closed access
SBStephan C. Bischoff
Stephan C. Bischoff
YBYves Boirie
Yves Boirie
TCTommy Cederholm
Tommy Cederholm
MCMichael Chourdakis
Michael Chourdakis
CCCristina Cuerda
Cristina Cuerda
RBRocco Barazzoni
Rocco Barazzoni

24 August 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HRHoyas Rodríguez
Hoyas Rodríguez
Miguel Leon-SanzMiguel Leon-Sanz
Miguel Leon-Sanz
Metabolic Syndrome (MetS) is a combination of risk factors for the development of cardiovascular disease (CVD) and type 2 diabetes. Different diagnostic criteria were proposed, but a consensus was reached in 2009 based on values of waist circumference, blood pressure, fasting glycemia, triglycerides, and high-density lipoprotein (HDL)-cholesterol levels. The main underlying etiologic factor is insulin resistance. The quality and quantity of individual macronutrients have an influence on the development and resolution of this syndrome. However, the main treatment goal is weight loss and a decrease in insulin resistance. A controlled energy dietary recommendation, together with moderate levels of physical activity, may positively change the parameters of MetS. However, there is no single dietary or exercise prescription that works for all patients. Dietary patterns such as Mediterranean-style, dietary approaches to stop hypertension (DASH), low-carbohydrate, and low-fat diets can ameliorate insulin resistance and MetS. Long-term adherence to a healthy lifestyle is key in assuring that individuals significantly reduce the risk of CVD and diabetes mellitus.

1 September 2015 in Nutrition
Verified
Journal Article
Closed access
Miguel Leon-SanzMiguel Leon-Sanz
Miguel Leon-Sanz
MBMax Brosa
Max Brosa
MPMercedes Planas
Mercedes Planas
AGAbelardo García-De-Lorenzo
Abelardo García-De-Lorenzo
SCSebastián Celaya-Pérez
Sebastián Celaya-Pérez
JHJulia Álvarez Hernández
Julia Álvarez Hernández

12 August 2022 in Clinical Nutrition
Verified
Journal Article
Open access
SBStephan C. Bischoff
Stephan C. Bischoff
RBRocco Barazzoni
Rocco Barazzoni
Luca BusettoLuca Busetto
Luca Busetto
MCMarjo J.E. Campmans-Kuijpers
Marjo J.E. Campmans-Kuijpers
VCVincenzo Cardinale
Vincenzo Cardinale
CCCristina Cuerda
Cristina Cuerda
Patients with chronic gastrointestinal (GI) disease such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, gastroesophageal reflux disease (GERD), pancreatitis, and chronic liver disease (CLD) often suffer from obesity because of coincidence (IBD, IBS, celiac disease) or related pathophysiology (GERD, pancreatitis and CLD). It is unclear if such patients need a particular diagnostic and treatment that differs from the needs of lean GI patients. The present guideline addresses this question according to current knowledge and evidence. The objective of the guideline is to give advice to all professionals working in the field of gastroenterology care including physicians, surgeons, dietitians and others how to handle patients with GI disease and obesity. The present guideline was developed according to the standard operating procedure for ESPEN guidelines, following the Scottish Intercollegiate Guidelines Network (SIGN) grading system (A, B, 0, and good practice point (GPP)). The procedure included an online voting (Delphi) and a final consensus conference. In 100 recommendations (3x A, 33x B, 24x 0, 40x GPP, all with a consensus grade of 90% or more) care of GI patients with obesity - including sarcopenic obesity - is addressed in a multidisciplinary way. A particular emphasis is on CLD, especially fatty liver disease, since such diseases are closely related to obesity, whereas liver cirrhosis is rather associated with sarcopenic obesity. A special chapter is dedicated to obesity care in patients undergoing bariatric surgery. The guideline focuses on adults, not on children, for whom data are scarce. Whether some of the recommendations apply to children must be left to the judgment of the experienced pediatrician. The present guideline offers for the first time evidence-based advice how to care for patients with chronic GI diseases and concomitant obesity, an increasingly frequent constellation in clinical practice.

12 August 2022 in United European Gastroenterology Journal
Verified
Journal Article
Open access
SBStephan C. Bischoff
Stephan C. Bischoff
RBRocco Barazzoni
Rocco Barazzoni
Luca BusettoLuca Busetto
Luca Busetto
MCMarjo J.E. Campmans-Kuijpers
Marjo J.E. Campmans-Kuijpers
VCVincenzo Cardinale
Vincenzo Cardinale
CCCristina Cuerda
Cristina Cuerda
Background: Patients with chronic gastrointestinal (GI) disease such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, gastroesophageal reflux disease (GERD), pancreatitis, and chronic liver disease (CLD) often suffer from obesity because of coincidence (IBD, IBS, celiac disease) or related pathophysiology (GERD, pancreatitis and CLD). It is unclear if such patients need a particular diagnostic and treatment that differs from the needs of lean GI patients. The present guideline addresses this question according to current knowledge and evidence.Objective: The objective of the guideline is to give advice to all professionals working in the field of gastroenterology care including physicians, surgeons, dietitians and others how to handle patients with GI disease and obesity.Methods: The present guideline was developed according to the standard operating procedure for European Society for Clinical Nutrition and Metabolism guidelines, following the Scottish Intercollegiate Guidelines Network grading system (A, B, 0, and good practice point [GPP]). The procedure included an online voting (Delphi) and a final consensus conference.Results: In 100 recommendations (3x A, 33x B, 24x 0, 40x GPP, all with a consensus grade of 90% or more) care of GI patients with obesity – including sarcopenic obesity – is addressed in a multidisciplinary way. A particular emphasis is on CLD, especially fatty liver disease, since such diseases are closely related to obesity, whereas liver cirrhosis is rather associated with sarcopenic obesity. A special chapter is dedicated to obesity care in patients undergoing bariatric surgery. The guideline focuses on adults, not on children, for whom data are scarce. Whether some of the recommendations apply to children must be left to the judgment of the experienced pediatrician.Conclusion: The present guideline offers for the first time evidence‐based advice how to care for patients with chronic GI diseases and concomitant obesity, an increasingly frequent constellation in clinical practice.

10 April 2023 in Clinical Nutrition
Verified
Journal Article
Closed access
SBStephan C. Bischoff
Stephan C. Bischoff
JOJohann Ockenga
Johann Ockenga
AEAhad Eshraghian
Ahad Eshraghian
RBRocco Barazzoni
Rocco Barazzoni
Luca BusettoLuca Busetto
Luca Busetto
CCCristina Cuerda
Cristina Cuerda